




The relative strengths and weaknesses of Sagent Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sagent Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Sagent Pharmaceuticals Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 344%, being 90% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	198,518
Cost of Goods Sold	0
Intangible Assets	93,730
Liabilities, Current	85,551
Liabilities, Non-Current	4,479
Other Assets	18,087
Other Compr. Net Income	-3,861
Other Expenses	178,388
Other Liabilities	15,706
Other Net Income	-678
Other Revenues	288,983
Property and Equipment	71,153
Research and Development	26,809
Selling, General and Administrative Expense	43,227

Output Variable	Value in 1000 USD
Assets	381,488
Liabilities	105,736
Expenses	248,424
Revenues	288,983
Stockholders Equity	275,752
Net Income	39,881
Comprehensive Net Income	37,950
BaseVar	514,585
ECR before LimitedLiability	262%
Economic Capital Ratio	344%